Yamaguchi University · University Hospital

Research keywordshepatocellular carcinoma・immune checkpoint therapy・durvalumab・tremelimumab・portosystemic shunt occlusion・portal hypertension endoscopy・metabolic-associated steatotic liver disease

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.2026 · Journal of gastroenterology and hepatology
• Caution Regarding Short-Term Increases in Ammonia Levels Following Splenic Artery Embolization.2026 · Hepatology research : the official journal of the Japan Society of Hepatology
• Development of a novel scoring system to determine the optimal timing of esophagogastroduodenoscopy following portosystemic shunt occlusion.2026 · PloS one
• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.2025 · Hepatology research : the official journal of the Japan Society of Hepatology

• 早期肝癌治療におけるリキッドバイオプシー検査による新たな統合インデックスの有用性2024 · 科学研究費助成事業
• 早期肝癌発見を可能とするリキッドバイオプシー検査体制の構築2023 · 科学研究費助成事業
• 早期肝癌発見を可能とするリキッドバイオプシー検査体制の構築2023 · 科学研究費助成事業

• Official profile